Breaking News: Kodiak's DAYBREAK Hits — Zenkuda and Tabirafusp-ted Both Positive
Breaking news: Kodiak Sciences announced this morning that both Zenkuda (tarcocimab tedromer) and tabirafusp-ted (KSI-501, tabirafusp alfa tedromer) met their primary endpoints in the Phase 3 DAYBREAK study in wet AMD — non-inferiority in vision gains vs. aflibercept at 1 year. Kodiak plans a Q4 20…
The 2026 Data Recap — What to Watch at AAO Next Week
John Kitchens, MD, and Scott Krzywonos take stock of the biggest retina data readouts of 2026 — from a superiority study from Ocular Therapeutix to a Kodiak comeback and a gene therapy from Beacon that could be the first approval for an inherited retinal disease since Luxturna in 2017. Also discuss…
Why the Best Retina Surgeons Keep Adapting Their Technique
In this episode of Retina Mentor Moments, John Kitchens, MD, sits down with Jayanth Sridhar, MD, to discuss how training across institutions, and continuing to learn from colleagues and trainees afterward, helps surgeons adapt their technique and improve patient care.
Dr. Sridhar is a vitreoretina…
Master the 5 Contexts of Coaching to Lead Real Estate Teams
Summary:
John Kitchens explores the shift from working as a real estate agent to operating as a team CEO by mastering five core coaching contexts. He outlines active listening to uncover core issues, relying on intuition to spot misalignment, maintaining curiosity through strong question-to-stateme…
The Smartest Way to Find Motivated Buyers & Sellers Using AI with Jay Kinder
Summary:
Hosts John Kitchens and Jay Kinder discuss the transformative role of AI in real estate customer acquisition and retention. They detail how agents can stop relying on generic drip campaigns and instead use AI to pinpoint hyper-targeted local avatars, analyze their specific motives, and del…
Breaking News: LUCIA Misses in Wet AMD — EyePoint Shifts to DME
Breaking news: EyePoint Pharmaceuticals announced this morning that LUCIA, the second pivotal Phase 3 trial of Duravyu (vorolanib, EYP-1901) for wet AMD, did not achieve the primary endpoint of statistical non-inferiority in mean change in BCVA versus on-label aflibercept. EyePoint is shifting reso…
Breaking News: Alcon Acquires Neurotech
Two pieces of news today, October 21, 2026.
Alcon announced the acquisition of Neurotech Pharmaceuticals for $550 million upfront, with additional milestone payments possible. John Kitchens, MD, and Scott Krzywonos break down why the pairing makes sense, what Alcon’s OR infrastructure could mean fo…
Big Pharma’s Retina Bets | Don D’Amico, MD, on BRUNELLO | RetinUp Turns One
RetinUp turns one year old. Before the birthday reflections, John Kitchens, MD, and Scott Krzywonos take stock of what the past eighteen months of retina acquisitions actually mean: Merck’s purchase of EyeBio for up to $3 billion, Eli Lilly’s acquisition of Adverum Biotechnologies for up to $262 mi…
#826: Why Being Recommended by AI Is the New Referral with Nick Krem
In this episode of Agent to CEO, John Kitchens sits down with Nick Krem to unpack why he pivoted his business, how he chooses which AI tools and partners to bet on, and why the agents who win won’t be the ones who master the tech fastest. They will be the ones who use it to get more face time with …
#826: Why Being Recommended by AI Is the New Referral with Nick Krem
In this episode of Agent to CEO, John Kitchens sits down with Nick Krem to unpack why he pivoted his business, how he chooses which AI tools and partners to bet on, and why the agents who win won’t be the ones who master the tech fastest. They will be the ones who use it to get more face time with …
পডকাস্ট সার্চ ইঞ্জিন
আপনি আমাদের ওয়েবসাইট ব্যবহার করতে পারেন3,833,196পডকাস্ট এবং197,054,651পর্বগুলি মানুষ, স্থান, বা বিষয় দ্বারা অনুসন্ধান করতে৷
I have no special talent. I am only passionately curious, and
I listen to podcasts.
‐ Albert "Llamacorn" Einstein
সম্পাদনা
পডকাস্ট ডেটাবেস আপ টু ডেট রাখতে সাহায্য করার জন্য আপনাকে ধন্যবাদ।
